key: cord-0973619-bfuo58tg
authors: Gong, Wenping; Wu, Xueqiong
title: Is the tuberculosis vaccine BCG an alternative weapon for developing countries to defeat COVID-19?
date: 2020-11-04
journal: Indian J Tuberc
DOI: 10.1016/j.ijtb.2020.10.012
sha: 2a746c0dfd9c70178eef246f4f32b2f074dba347
doc_id: 973619
cord_uid: bfuo58tg

BACKGROUD: Coronavirus disease (COVID-19) is a new respiratory infectious disease, and there is no vaccine currently. Previous studies have found that BCG vaccination can provide extensive protection against respiratory infectious diseases. METHODS: Herein, we obtained the latest data from the World Health Organization (WHO) as of August 12, 2020, and determined the relationship between three parameters (including the BCG vaccination coverage, human development index (HDI), and transmission classifications) and the incidence rate and mortality of COVID-19. RESULTS: The results showed that the morbidity and mortality of COVID-19 in countries with BCG vaccination recommendation were significantly lower than these in countries without BCG vaccination recommendation, and countries with lower HDI ​​have lower morbidity and mortality. In addition, we also found that the mode of virus transmission is also related to the morbidity and mortality of COVID-19. CONCLUSIONS: Although our data supports the hypothesis that BCG vaccination is beneficial in reducing the morbidity and mortality of COVID-19, the data supporting this result may be inaccurate due to many confounders such as PCR testing rate, population characteristics, and protection strategies, the reliability of this result still needs to be verified by clinical trials.

showed that the morbidity and mortality of COVID-19 in countries with BCG vaccination 10 recommendation were significantly lower than these in countries without BCG vaccination 11 recommendation, and countries with lower HDI have lower morbidity and mortality. In addition, we 12 also found that the mode of virus transmission is also related to the morbidity and mortality of 13 COVID-19. Conclusions: Although our data supports the hypothesis that BCG vaccination is 14 beneficial in reducing the morbidity and mortality of COVID-19, the data supporting this result may be were divided into three levels. We found that the COVID-19 incidence rate of countries with BCG 50 recommendation was significantly lower than that of countries without BCG recommendation ( Figure   51 1A), and the COVID-19 mortality rate of countries with BCG coverage of ≥ 90 was also significantly 52 lower ( Figure 1B) . These data indicated that higher BCG coverage might have a significant effect on 53 reducing the incidence rate and mortality of COVID-19. According to the data released by WHO, most 54 countries nationally recommend BCG vaccination are LDCs, LLDCs, and SIDs, but the HDI of these 55 countries is generally low. In order to verify the relationship between HDI and the incidence rate and 56 mortality of COVID-19, we divided all the countries into four levels according to the Human 57 Development Report 2019 released by the United Nations Development Programme. The data 58 indicated that countries with a lower HDI had lower COVID-19 incidence ( Figure 1C ) and mortality 59 ( Figure 1D ). Countries with low HDI are mainly concentrated in LDCs, while the BCG vaccination 60 rate in LDCs is generally higher than 90%. This result once again shows that increasing the coverage of 61 BCG can effectively reduce the morbidity and mortality of COVID-19. Open and cooperation are the magic weapon to defeat the COVID-19 pandemic 94 It is therefore our hope that this study will give people in a gloomy world a ray of light and 95 confidence in defeating the epidemic, provide an alternative vaccine for high-risk population (such as 96 health care workers, the elderly, etc.), and win time for the development of COVID-19 vaccines. 

Evolution of the COVID-19 vaccine development 143 landscape

BCG vaccine protection from severe 145 coronavirus disease 2019 (COVID-19)

BCG-induced trained immunity: can it offer protection against 148 COVID-19?

Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of 151 SARS-CoV-2 Infection

SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated 153

Stop playing with data: there is no sound 155 evidence that Bacille Calmette-Guérin may avoid SARS-CoV-2 infection (for now)

BCG as a game-changer 160 to prevent the infection and severity of COVID-19 pandemic? Allergologia et immunopathologia

How to stop COVID-19 fuelling a resurgence of AIDS, malaria and tuberculosis

Economic impact of broadband in LDCs, LLDCs and SIDs

International Telecommunication Union